Sobre Artax Biopharma
Artax Biopharma is developing the next generation of drugs targeting the interaction between TCR and Nck, which is responsible for T-cell activation. Specific control over T-cells through TCR, provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.
Galería Artax Biopharma 1
Datos Artax Biopharma
Total inversión
1.520.000€
Rondas inversión
-
Early/Startup
NO DISPONIBLE
Inversores Artax Biopharma 4
Acceleradoras Artax Biopharma 0
Artax Biopharma no ha pasado por aceleradoras
Noticias Artax Biopharma 0
Artax Biopharma no tiene ninguna noticia disponible.